1. U.S. Food & Drug Administration. FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer [media release]. 16 Dec 2022. https://www.fda.gov/.
2. Narayan VM, Dinney CPN. Intravesical gene therapy. Urol Clin North Am. 2020;47(1):93–101.
3. Ferring Pharmaceuticals. Ferring receives approval from U.S. FDA for Adstiladrin for high-risk, BCG-unresponsive non-muscle invasive bladder cancer [media release]. 16 Dec 2022. https://www.ferring.com/.
4. US National Institutes of Health. ClinicalTrials.gov trial record (NCT03710876). 2021. https://clinicaltrials.gov/. Accessed 7 Feb 2023.
5. Ferring Pharmaceuticals. ADSTILADRIN® (nadofaragene firadenovec-vncg) suspension, for intravesical use: US prescribing information. 2022. https://www.fda.gov/. Accessed 27 Jan 2023.